Clinical Trial Update: VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on the Phase 1/Phase 2 trial of VST-1001 (dilute fluorescein) for lymphatic mapping and localization of lymph nodes in breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• VST-1001 (dilute fluorescein)

Snippet

Sponsor: Vestan, Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN